Last reviewed · How we verify

Exparel + Bupivacaine

Pacira Pharmaceuticals, Inc · FDA-approved active Small molecule

Exparel is a liposomal formulation of bupivacaine that provides prolonged local anesthetic effect by slowly releasing bupivacaine from lipid vesicles at the injection site.

Exparel is a liposomal formulation of bupivacaine that provides prolonged local anesthetic effect by slowly releasing bupivacaine from lipid vesicles at the injection site. Used for Infiltration anesthesia for surgical anesthesia, Interscalene brachial plexus nerve block, Transversus abdominis plane (TAP) block.

At a glance

Generic nameExparel + Bupivacaine
SponsorPacira Pharmaceuticals, Inc
Drug classLocal anesthetic (liposomal formulation)
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaAnesthesia / Pain Management
PhaseFDA-approved

Mechanism of action

Bupivacaine is an amide local anesthetic that blocks sodium channels in nerve cell membranes, preventing depolarization and nerve signal transmission. The liposomal encapsulation (DepoFoam technology) allows sustained release of bupivacaine over an extended period (up to 72 hours), providing longer-lasting anesthesia compared to standard bupivacaine formulations.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: